Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis

Apoptosis

Volumn 8, Issue 3, 2003, Pages 237-249

  Chawla Sarkar, M ^a   Lindner, D J ^a   Liu, Y F ^a   Williams, B R ^b   Sen, G C ^b   Silverman, R H ^b   Borden, E C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiogenesis; Anti tumor; Apoptosis; Interferon; ISGs

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CASPASE; CASPASE 4; CASPASE 8; CELL PROTEIN; CYTOKINE; DEATH ACTIVATING PROTEIN KINASE; ECALECTIN; FAS ANTIGEN; FAS LIGAND; GALECTIN; GAMMA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 1; PROTEIN KINASE; PROTEIN XAF 1; SCRAMBLASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; CANCER CELL DESTRUCTION; CELL DEATH; ENZYME ACTIVITY; GENE CONTROL; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; HUMANS; INTERFERONS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 0037790592     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023668705040     Document Type: Short Survey

References (104)

1. Borden EC, Williams BRG. Interferons. In: Bast RC Jr, Holland JF, Gansler TS, eds. Cancer Medicine, 5th edition, Toronto: B.C. Decker Inc 2000: 815-824.
2. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to interferons. Ann Rev Biochem 1998; 67: 227-264.
3. Pfeffer LM, Dinarello CA, Herbermann RB, et al. Biological properties of recombinant α-interferons: 40th anniversary of the discovery of Interferons. Cancer Res 1998; 58: 2489-2499.
4. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421.
5. Leaman DW, Chawla-Sarkar M, Vyas K, Ozdemir A, Borden EC. Greater potency of IFN-β compared to IFN-α 2 in inducing IFN stimulated genes in melanoma: Identification of new ISGs by oligonucleotide microarray. Submitted 2002.
6. Der SD, Zhou A, Williams BRG, Silverman RH. Identification of genes differentially regulated by interferon-a, b or g using olignucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-15628.
7. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjpe JM, Silverman RH, Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 2001; 69: 912-920.
8. Grander D, Einhorn S. Interferon and malignant disease - How does it work and why doesn't it always? Acta Oncol 1998; 37: 331-338.
9. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-β compared with IFN-α2: Correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7: 1821-1831.
10. Morrison BH, Bauer JA, Kalvakolanu DV, Lindner DJ. Inositol hexakisphosphate kinase 2 mediates growth suppressive and apoptotic effects of interferon-beta in ovarian carcinoma cells. J Biol Chem 2001; 276: 24965-24970.
11. Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl2 related proteins regulate type I interferon induced apoptosis in mutiple myeloma. Blood 2001; 98: 2183-2192.
12. Ossina NK, Cannas A, Powers VC, et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997; 272: 16351-16357.
13. Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of IFN-alpha induced apoptosis in malignant cells. Oncogene 2002; 21: 1251-1262.
14. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997; 8: 343-352.
15. Otsuki T, Yamada O, Sakaguchi H. Human myeloma cell apoptosis induced by interferon-α2. Br J Haematol 1998; 103: 518-529.
16. Balkwill F, Taylor-Papadinitriou J. Interferon affects both G1 and S+ G2 in cells stimulated from quiescence to growth. Nature 1978; 274: 798-800.
17. Kumar A, Atlad I. Interferon-α induces the expression of retinoblastoma gene product in human burkitt lymphoma Daudi cells: Role in growth regulation. Proc Natl Acad Sci USA 1992; 89: 6599-6603.
18. Tienfenbrun N, Melamed D, Levy N. Alpha interferon suppresses the cyclin D3 and cdc25 A genes, leading to reversible G0-like arrest. Mol Cell Biol 1996; 16: 3934-3944.
19. Subramaniam PS, Cruz PE, Hobeika AC, Johnson HM. Type I interferon induction of the Cdk-inhibitor p21 WAF1 is accompanied by order G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene 1998; 16: 1885-1890.
20. RaffM. Cell suicide for beginners. Nature 1998; 39: 119-122.
21. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
22. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281: 1305-1308.
23. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424.
24. Balachandran S, Roberts PC, Kipperman T, et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol 2000; 74: 1513-1523.
25. Spets H, Georgi-Hemming P, Silsajon J, Nilsson K, Jernberg-Wiklund H. Fas/Apo-1 mediated apoptosis is activated by IFN-γ and IFN-α in IL-6 dependent and IL-6 independent multiple myeloma cell lines. Blood 1998; 92: 2914-2923.
26. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997; 89: 957-964.
27. Buechner SA, Wernli M, Harr T, Hahn S, Itin P, Erb P. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand induced suicide. J Clin Invest 1997; 100: 2691-2696.
28. Ahn EY, Pan G, Vickers SM, McDonald JM. IFN-gamma upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 2002; 100: 445-451.
29. Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 1999; 82: 727-736.
30. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I Interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T Cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451.
31. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
32. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690.
33. Ruiz-Ruiz C, Lopez-Rivas A. Mitochondria-dependent and independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 2002; 365: 825-832.
34. Leaman DW, Chawla-Sarkar M, Vyas K, et al. Identification of X-linked inhibitor of apoptosis associated factor-1 as and IFN stimulated gene that augments TRAIL/Apo2L-induced apoptosis. J Biol Chem 2002; 277: 28504-28511.
35. Liston P, Fong W, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anticaspase activity. Nature Cell Biol 2001; 3: 128-133.
36. Deveraux QL, Takahashi R, Salvesan GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304.
37. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000; 70: 113-122.
38. Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res, 2000; 60: 5673-5680.
39. Kim PK, Mahidhara R, Seol DW. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist Updat 2001; 4: 293-296.
40. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994; 368: 258-261.
41. Morrison BH, Bauer JA, Hu J, et al. Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics. Oncogene 2002; 2: 1882-1889.
42. York JD, Odom AR, Murphy R, Ives EB, Wente SR. A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 1999; 285: 96-100.
43. Hanakahi LA, Bartlet-Jones M, Chappell C, Pappin D, West SC. Binding of inositol phosphate to DNA-PK and stimulation of double-strand break repair. Cell 2000; 102: 721-729.
44. Nguyen H, Hiscott J, Pitha PM. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 1997; 8: 293-312.
45. Tanaka N, Ishihara M, Kitagawa M, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829-839.
46. Tamura T, Ishihara M, Lamphier MS, et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995; 376: 596-599.
47. Kano A, Haruyama T, Akaike T, Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem Biophys Res Commun 1999; 257: 672-677.
48. Heylbroeck C, Balachandran S, Servant MJ, et al. The IRF-3 transcription factor mediates Sendai virus-induced apoptosis. J Virol 2000; 74: 3781-3792.
49. Gabriele L, Phung J, Fukumoto J, et al. 3rd Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med 1999; 190: 411-421.
50. Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. Impaired alpha-interferon signaling in transitional cell carcinoma: Lack of p48 expression in 5637 cells. Cancer Res 2001; 6: 2261-2266.
51. Hovanessian AG, Brown RE, Kerr IM. Synthesis of low molecular weight inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature 1977; 268: 537-540.
52. Meurs E, Chong K, Galabru J, et al. Molecular cloning and characterization of the double-stranded RNA-activated protein kinase induced by IFN. Cell 1990; 62: 379-390.
53. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene 1999; 18: 6112-6120.
54. Sen GC. Viruses and interferons. Ann Rev Microbiol 2001; 55: 255-281.
55. Peters GA, Hartmann R, Qin J, Sen GC. Modular structure of PACT: Distinct domains for binding and activating PKR. Mol Cell Biol 2001; 21: 1908-1920.
56. Tan SL, Katze MG. The emerging role of the interferon induced PKR protein kinase as an apoptotic effector: A new face of death? J IFN Cytokine Res 1999; 19: 543-554.
57. Der SD, Yang YL, Weissmann C, Williams BR. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc Natl Acad Sci USA 1997; 94: 3279-3283.
58. Donze O, Dostie J, Sonenberg N. Regulatable expression of the interferon induced double-stranded RNA dependent protein kinase PKR induces apoptosis and Fas receptor expression. Virology 1999; 256: 322-329.
59. Jagus R, Joshi B, Barber GN. PKR, apaptosis and cancer. Int J Biochem Cell Biol 1999; 31: 123-138.
60. Balachandran S, Kim CN, Yeh WC, Mak, TW, Bhalla K, Barber GN. Activation of the ds-RNA-dependent protein kinase, PKR induces apoptosis through FADD-mediated death signaling. EMBOJ 1998; 17: 6888-6902.
61. Justesen J, Hartmann R, Kjeldgaard NO. Gene structure and function of the 2′-5′-oligoadenylate synthetase family. Cell Mol Life Sci 2000; 57: 1593-1612.
62. Clemens MJ, Williams BR. Inhibition of cell-free protein synthesis by pppA2′p5′A2′p5′A: A novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell 1978; 3: 565-572.
63. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNAse: A uniquely regulated mediator of interferon action. Cell 1993; 72: 753-765.
64. Zhou A, Nie H, Silverman RH. Analysis and origins of the human and mouse RNase L genes: Mediators of interferon action. Mamm Genome 2000; 11: 989-992.
65. Dong B, Silverman RH. 2-5A-dependent RNase molecules dimerize during activation by 2-5A. J Biol Chem 1995; 270: 4133-4137.
66. Cole JL, Carroll SS, Kuo LC. Stoichiometry of 2′,5′-oligoadenylate-induced dimerization of ribonuclease L. A sedimentation equilibrium study. J Biol Chem 1996; 271: 3979-3981.
67. Castelli JC, Hassel BA, Maran A, et al. The role of 2′-5′ oligoadenylate-activated ribonuclease L in apoptosis. Cell Death Differ 1998; 5: 313-320.
68. Castelli JC, Hassel BA, Wood KA, et al. A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system. J Exp Med 1997; 186: 967-972.
69. Zhou A, Paranjape J, Brown TL, et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J 1997; 16: 6355-6363.
70. Zhou A, Paranjape JM, Hassel BA, et al. Impact of RNase L overexpression on viral and cellular growth and death. J Interferon Cytokine Res 1998; 18: 953-961.
71. Rusch L, Dong B, Silverman RH. Monitoring Activation of RNase L by 2′,5′-oligoadenylates using purified recombinant enzyme and intact malignant glioma cells. Methods in Enzymology 2001; 342: 10-20.
72. Rusch L, Zhou A, Silverman RH. Caspase-dependent apoptosis by 2′,5′-oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon Cytokine Res 2000; 20: 1091-1100.
73. Diaz-Guerra M, Rivas C, Esteban M. Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology 1997; 236: 354-363.
74. Iordanov MS, Paranjape JM, Zhou A, et al. Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: Involvement of RNase L, protein kinase R, and alternative pathways. Mol Cell Biol 2000; 20: 617-627.
75. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L (RNase L) gene in hereditary prostate cancer 1 (HPC1)-linked families. Nat Genet 2002; 30: 181-184.
76. Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70: 1299-1304.
77. Wang L, McDonnell SK, Elkins DA, et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 2002; 71: 116-123.
78. Rennert H, Bercovich D, Hubert A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, Is associated with prostate cancer in Ashkenazi jews. Am J Hum Genet 2002; 71(4): 981-984.
79. Casey G, Neville PJ, Plummer SJ, et al. RNASEL R462Q variant increases risk of prostate cancer. Nat Genet 2002; 32(4): 581-583.
80. Ghosh A, Sarkar SN, Rowe TM, Sen GC. A specific isozyme of 2′-5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J Biol Chem 2001; 276: 25447-25455.
81. Lavau C, Marchio A, Fagioli M, et al. The acute promyelocytic leukaemia-associated PML gene is induced by interferon. Oncogene 1995; 11: 871-876.
82. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20: 266-272.
83. Saita N, Goto E, Yamamoto T, et al. Association of galactin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 2002; 128: 42-50.
84. Kageshita T, Kashio Y, Yamauchi A, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002; 99: 809-816.
85. Zhou Q, Zhao J, Al-Zoghaibi F, et al. Transcriptional control of the human plasma membrane phospholipid scramblase 1 gene is mediated by interferon-alpha. Blood 2000; 95: 2593-2599.
86. Silverman RH, Halloum A, Zhou A, et al. Suppression of ovarian carcinoma cell growth in vivo by the interferon-inducible plasma membrane protein, phospholipid scramblase 1. Cancer Res 2002; 62: 397-402.
87. Zhou Q, Zhao J, Wiedmer T, Sims PJ. Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1. Blood 2002; 99: 4030-4038.
88. Sun J, Nanjundan M, Pike LJ, Wiedmer T, Sims PJ. Plasma membrane phospholipid scramblase 1 is enriched in lipid rafts and interacts with the epidermal growth factor receptor. Biochemistry 2002; 41: 6338-6345.
89. Sun J, Zhao J, Schwartz MA, Wang JY, Wiedmer T, Sims PJ. c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1. J Biol Chem 2001; 276: 28984-28990.
90. Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A. Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev 1995; 9: 15-30.
91. Inbal B, Cohen O, Polak-Charcon S, et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180-184.
92. Kleinerman ES, Kurzrock R, Wyatt D, Quesada JR, Gutterman JU, Fidler IJ. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant-interferon. Cancer Res 1986; 46: 5401-5405.
93. Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: Interferon resistant and -sensitive cell lines. Proc Natl Acad Sci USA 1982; 79: 3265-3269.
94. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur J Immunol 2001; 31: 3138-3146.
95. Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001; 166: 5407-5415.
96. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58: 808-814.
97. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987; 47: 5155-5161.
98. Lindner DJ. Interferons as antiangiogenic agents. Curr Oncol Rep 2002; 4: 510-514.
99. Izawa JI, Sweeney P, Perrotte P, et al. Inhibition of tumorigenicity and merastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002; 8: 1258-1270.
100. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247.
101. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002; 169: 847-885.
102. Kumar-Sinha C, Varambally S, Sreekumar A, Chinnaiyan AM. Molecular cross-talk between the TRAIL and interferon signaling pathways. J Biol Chem 2002; 277: 575-585.
103. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521-530.
104. Xaus J, Cardo M, Valledor AF, Soler C, Lloberas J, Celada A. Interferon gamma induces the expression of p21 waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity 1999; 11: 103-113.